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Summary
Objective: To compare the safety and efﬁcacy of acetaminophen extended-release (APAP ER) with rofecoxib for the management of pain
associated with knee osteoarthritis (OA).
Methods: Four hundred and three adult patients with moderate pain secondary to knee OA were randomized to receive APAP ER 1300 mg
three times daily, rofecoxib 12.5 mg once daily, or rofecoxib 25 mg once daily. Primary end point was change from baseline at week 4 in the
Western Ontario and McMaster Universities Osteoarthritis Index pain subscale score using a visual analog scale. This 4-week study was con-
ducted at 23 US research sites from October 1999 to October 2000.
Results: APAP ER was noninferior to rofecoxib 12.5 mg because the upper 95% conﬁdence limit (CL) for the least squares mean (LSM)
change from baseline (35.27 mm at week 4) did not exceed the prespeciﬁed noninferiority limit of 50 mm. The upper CL (57.39 mm) exceeded
the noninferiority limit for APAP ER compared with rofecoxib 25 mg at week 4. There were no signiﬁcant differences among groups in the
overall incidence of adverse events.
Conclusion: APAP ER 3900 mg daily was noninferior to rofecoxib 12.5 mg daily, but noninferiority was not established to rofecoxib 25 mg
daily. APAP ER was well tolerated and no safety issues were identiﬁed. Based on the results of this study, APAP ER 3900 mg daily is an
alternative to nonsteroidal anti-inﬂammatory drugs (NSAIDs), such as rofecoxib, in treating pain associated with knee OA.
ª 2008 Published by Elsevier Ltd on behalf of Osteoarthritis Research Society International.
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The management of osteoarthritis (OA) remains challenging,
despitegreater awarenessamongprimary care providers and
rheumatologists of the importance of lifestyle modiﬁcations
and theavailability of new therapies.Nonpharmacologic inter-
ventions including exercise and bracing are commonly rec-
ommended but often not sufﬁcient to adequately manage
pain1e3. Thus, analgesic drug therapy is frequently required.
Because OA is more prevalent in the elderly e many of
whom have comorbiditiese selection of an analgesic is often
complicated3,4.Additionally, elderlypatientsareatgreater risk
for gastrointestinal (GI) bleeding secondary to use of nonste-
roidal anti-inﬂammatory drugs (NSAIDs)5.
Aspirin and other NSAIDs have been utilized for more
than a century to effectively relieve musculoskeletal pain6,
although associated adverse GI side effects have long
been recognized5. This has led to the development of anal-
gesics with lower incidence of GI side effects7. Cyclooxyge-
nase (COX)-2-selective inhibitors were introduced in 1999,*Address correspondence and reprint requests to: Dr Thomas J.
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1providing analgesia equivalent to older NSAIDs with mark-
edly lower rates of GI ulcers and related complications8.
Prophylactic use of misoprostol and proton pump inhibitors
also may be appropriate for patients on chronic NSAID ther-
apy who are at increased risk for upper GI adverse effects1.
Peripheral edema, congestive heart failure, and in-
creases in blood pressure have long been observed with
traditional NSAID use9,10. More recent data suggest that
COX-2-selective inhibitors are also associated with in-
creased risk of myocardial infarction, stroke11, and adverse
renal and arrhythmia events12. This has resulted in a more
detailed investigation of the cardiovascular risk of not only
COX-2-selective inhibitors, but also traditional NSAIDs. A
recent meta-analysis of all randomized, controlled trials of
COX-2-selective inhibitors conﬁrmed their increased cardio-
vascular risk compared with placebo13. The risk was similar
to the increased cardiovascular risk seen with traditional
NSAIDs, with the exception of naproxen, which was similar
in risk to placebo. The mechanisms responsible are not well
understood.
Controversy surrounding COX-2-selective inhibitors has
prompted careful reevaluation of the risks and beneﬁts of
NSAID use14. Thus, an analgesic agent, such as acetamino-
phen (APAP), which has not been shown in randomized clin-
ical trials to be associated with adverse GI or cardiovascular
risks, provides an alternative that may be particularly
2 T. J. Schnitzer et al.: Acetaminophen ER vs rofecoxib in knee OAattractive for patients with OA at higher risk for complica-
tions15. APAP has been recommended by the American Col-
lege of Rheumatology (ACR) as the ﬁrst-line treatment for
pain associated with OA1. An extended-release (ER) formu-
lation permitting less frequent dosing has recently been intro-
duced and has demonstrated efﬁcacy in treating knee OA
pain16.
Few previous studies have been designed to directly com-
pare NSAIDs with APAP, and their results have been incon-
sistent17e19. APAP ER has not been compared previously
with a COX-2-selective inhibitor for knee OA. Therefore, this
4-week study was conducted to compare the safety and efﬁ-
cacy of APAP ER (given three times daily) with two standard
doses of rofecoxib (12.5 mg and 25 mg given once daily) for
the management of pain associated with knee OA.Patients and methodsSTUDY DESIGN AND SELECTION OF PARTICIPANTSThis multicenter, randomized, double-blind study compared treatment
outcome with APAP ER or rofecoxib in patients experiencing pain associated
with knee OA. Investigators at 23 centers in the US participated in the study
from October 15, 1999 to October 27, 2000. The study protocol and amend-
ments were reviewed by an ethics committee or received approval from an
institutional review board (IRB), and written informed consent was obtained
from each patient before enrollment.
Criteria for enrollment in the study included age  40 years and symptom-
atic idiopathic knee OA lasting at least six months and characterized by at
least moderate pain requiring treatment three or more days per week with
an analgesic or anti-inﬂammatory agent for at least three months. Patients
also had to fulﬁll at least two of the ﬁve criteria established by the ACR for
idiopathic knee OA20. Additionally, patients were required to have radio-
graphic evidence of OA21, normal laboratory test values, physical ability clas-
siﬁed as ACR functional class I or II22, and a historically positive response to
the regular use of analgesics or anti-inﬂammatory agents for the treatment of
knee OA pain. Patients must also have reported at least moderate pain when
asked to evaluate their maximum pain intensity on a 5-point scale during
a 24-h period. All women of childbearing potential were required to use an
effective method of birth control, have negative serum pregnancy results,
and not be lactating.
Patients were excluded from the study if they had a history of surgery,
trauma, or arthroscopy of the study joint within the previous 12 months,
any other type of arthritis, active malignancies, or any active GI, cardiovas-
cular, renal, hepatic, neurologic, or psychiatric disease. Additionally, patients
were excluded if they had been using anticonvulsants, tranquilizers, or anti-
depressants in the previous three months and had not been stabilized on
therapy; had been using glucosamine or chondroitin sulfate in the previous
six months without having been stabilized on therapy; had undergone treat-
ment with hyaluronan in the previous six months; had used intra-articular or
oral corticosteroids in the previous two months; or had required the use of
concomitant medications that could have confounded the assessment of ef-
ﬁcacy of study drug treatments (APAP, NSAIDs, aspirin, over-the-counter
medications that may contain analgesics, narcotic analgesics, herbal prepa-
rations with potential analgesic qualities, and topical analgesics).
During the screening visit, patients received a physical examination, in-
cluding a clinical laboratory proﬁle and knee joint assessment. Patients
also completed the Western Ontario and McMaster Universities OA Index
(WOMAC) using a visual analog scale (VAS) to evaluate pain, stiffness,
and physical function. Following the screening visit, potential study patients
completed a washout period during which they were prohibited from taking
their usual arthritis medications within ﬁve drug half-lives before randomiza-
tion (ranged from three to ﬁve days, depending on the drug). Following the
washout period, enrollment was limited to patients who experienced an ar-
thritis ﬂare, deﬁned as an increase of the WOMAC pain subscale score of
20e80% relative to the screening visit. Those with signs of active inﬂamma-
tion of the study joint (i.e., redness, warmth, or bulging effusion) after the
washout period were not eligible for randomization.
Patients were randomized in a 1:1:1 ratio to receive the following treat-
ments in a double-blind, double-dummy fashion: APAP ER 3900 mg daily
(1300 mg every 8 h), rofecoxib 12.5 mg once daily, or rofecoxib 25 mg
once daily for four weeks. Patients randomized to receive APAP ER were in-
structed to dose every 8 h and received two APAP ER caplets and two rofe-
coxibeplacebo capsules at each dosing interval. Patients randomized to
receive rofecoxib 12.5 mg were instructed to dose every 8 h and received
one rofecoxib capsule, one rofecoxibeplacebo capsule, and two APAP
EReplacebo caplets as the ﬁrst dose in the morning, and two APAP ERe
placebo caplets and two rofecoxibeplacebo capsules at the second and thirddosing intervals. Patients randomized to receive rofecoxib 25 mg were in-
structed to dose every 8 h and received two rofecoxib capsules and two
APAP EReplacebo caplets as the ﬁrst dose in the morning, and two
APAP EReplacebo caplets and two rofecoxibeplacebo capsules at the sec-
ond and third dosing intervals.STUDY ASSESSMENTSFollow-up visits were conducted at 1, 2, and 4 weeks following the base-
line visit or upon discontinuing participation in the study. At each visit, a joint
examination was performed, and the patient’s weight, blood pressure, adher-
ence to the dosing regimen, and need for additional analgesia were as-
sessed. The investigator recorded his or her impression of therapeutic
response, and the patient recorded his or her own assessment of the med-
ication as an analgesic for the study knee joint (both assessments rated on
a 0e4 scale; 0¼ poor and 4¼ excellent). Each patient then completed the
WOMAC by VAS to evaluate pain, stiffness, and physical function. At the ﬁ-
nal visit, the investigator recorded his or her global impression of the thera-
peutic response, and the patient recorded his or her overall impression of the
study medication.
The primary efﬁcacy end point in this study was change from baseline in
the WOMAC pain subscale score at week 4. Secondary efﬁcacy end points
included change from baseline in the WOMAC pain subscale score at weeks
1 and 2; change from baseline in the WOMAC stiffness and physical function
subscale scores at weeks 1, 2, and 4; the investigator’s impression of the
therapeutic response and the patient’s impression of the medication as an
analgesic at weeks 1, 2, and 4; the investigator’s global impression of the
therapeutic response at week 4 or the ﬁnal visit; and the patient’s overall im-
pression of the study medication at week 4 or the ﬁnal visit.
Safety was assessed by careful monitoring of adverse events (AEs)
throughout the course of the study, which was based on signs and symptoms
reported by the patient or observed by the investigator. In addition, each pa-
tient was asked the nonspeciﬁc question: ‘‘Have you experienced any un-
usual signs or symptoms since your last visit?’’ All responses were
recorded using standard medical terminology. Details regarding the AEs,
including information about medication used to treat the AEs, were recorded.
All serious AEs were reported to the sponsor, and the study investigators
analyzed the potential relationship to study medication.STATISTICAL METHODSA sample size of at least 100 patients per treatment group was chosen to
provide 90% power to detect a difference between rofecoxib and APAP ER
of 50 mm in improvement from baseline in the WOMAC pain subscale score
at week 4 assuming a common standard deviation of 120. The changes from
baseline in the WOMAC subscale scores for pain, stiffness, and physical
function were analyzed with analyses of variance (ANOVA), with treatment,
investigator, and treatment by investigator as interaction terms in the model.
Noninferiority was established if the upper one-sided 95% conﬁdence limit
(CL) for the difference in least squares mean (LSM) change from baseline
was 50 mm. A difference of 50 mm represents 10% of a maximum score
of 500 mm on the pain subscale. If noninferiority was established, statistical
superiority was tested by determining if the upper one-sided 95% CL of the
difference excluded zero. Statistical superiority was not tested if noninferior-
ity was not established.
Similar testing procedures were used for the secondary efﬁcacy end
points obtained from the WOMAC. Although not speciﬁed explicitly in the
protocol, a difference of 170 mm represents 20% of an expected baseline
score of approximately 850 mm in the physical function subscale, and a dif-
ference of 20 mm represents 20% of an expected baseline score of 100 mm
on the stiffness subscale. The remaining secondary efﬁcacy end points were
analyzed similarly, although there were no prespeciﬁed noninferiority limits.
The analyses of the primary efﬁcacy end point were based on the per-
protocol (PP) population. Patients were included in the PP population if
they had taken at least 80% of assigned doses, returned to the study center
for follow-up visits, and complied with study restrictions. Patients who had
taken at least one dose of medication and completed at least one post-base-
line efﬁcacy assessment were included in the intent-to-treat (ITT) population.
A safety evaluation was completed for all patients who had taken at least one
dose of blinded study medication. AE rates were compared using Fisher’s
exact tests. All statistical analyses were performed with SAS version 8.2
Software (SAS Institute Inc; Cary, NC, USA).ResultsCHARACTERISTICS OF STUDY PATIENTSOf 403 patients randomized in this study, 136 were
assigned to the APAP ER group, 138 to the rofecoxib
N=403
Subjects Randomized
APAP ER
n=136
Rofecoxib 12.5 mg
n=138
Rofecoxib 25 mg
n=129
n=117
Completed
n=19
Withdrawn
n=121
Completed
n=17
Withdrawn
n=109
Completed
n=20
Withdrawn
Adverse Event 8
Protocol Violation   6
Lost to Follow-Up  0
Lack of Efficacy 2
Other 3
Adverse Event 9
Protocol Violation   2
Lost to Follow-Up  1
Lack of Efficacy 5
Other 0
Adverse Event 9
Protocol Violation   6
Lost to Follow-Up  1
Lack of Efficacy 2
Other 2
Fig. 1. Patient disposition.
3Osteoarthritis and Cartilage Vol. 17, No. 112.5-mg group, and 129 to the rofecoxib 25-mg group
(Fig. 1). Overall, 56 patients (13.9%) withdrew from the
study; withdrawal number was comparable among groups.
Demographic and baseline characteristics for the ITT popu-
lation were similar among groups (Table I). The mean age
of patients was 59.8 years, and 37.5% of the patients
were male. Fifty-six percent of patients treated with APAP
ER, 55% treated with rofecoxib 12.5 mg, and 52% treated
with rofecoxib 25 mg were 100% compliant with studyTable
Demographic and baseline characteristics for subjects
Characteristics APAP ER 3900 mg TID (n¼ 126)
Gender, n (%)
Men 51 (40.5)
Women 75 (59.5)
Age (years)
Mean (SD) 60.9 (10.8)
Body mass index (kg/m2)
Mean (SD) 32.4 (7.7)
Race, n (%)
Caucasian 101 (80.2)
African American 20 (15.9)
Other 5 (4.0)
Baseline knee pain, n (%)
Moderate 40 (31.7)
Moderately severe 73 (57.9)
Severe 13 (10.3)
Concomitant medication, n (%) 110 (87.3)
Concomitant use of glucosamine
or chondroitin
15 (11.9)
WOMAC pain subscale
Mean (SD) 290.3 (101.2)
WOMAC stiffness subscale
Mean (SD) 117.8 (43.5)
WOMAC physical function subscale
Mean (SD) 972.3 (341.8)
QD¼ once daily; TID¼ three times daily.medication. Study medication compliance was at least
80% for 98%, 99%, and 98% of patients in the APAP ER,
rofecoxib 12.5-mg, and rofecoxib 25-mg groups,
respectively.EFFICACY RESULTSWhen the primary end point was tested, APAP ER was
therapeutically noninferior to rofecoxib 12.5 mg in theI
included in the ITT analysis by treatment group
Rofecoxib 12.5 mg QD (n¼ 129) Rofecoxib 25 mg QD (n¼ 121)
48 (37.2) 42 (34.7)
81 (62.8) 79 (65.3)
60.8 (10.2) 57.5 (11.5)
33.0 (7.2) 33.7 (9.0)
107 (82.9) 96 (79.3)
20 (15.5) 14 (11.6)
2 (1.6) 11 (9.1)
49 (38.0) 39 (32.2)
69 (53.5) 70 (57.9)
11 (8.5) 12 (9.9)
109 (84.5) 105 (86.8)
22 (17.1) 16 (13.2)
285.9 (102.8) 310.7 (107.2)
122.2 (44.0) 130.5 (45.0)
987.2 (335.6) 1066.4 (377.8)
Table II
LSM change from baseline in WOMAC pain, physical function, stiffness subscales, patient’s overall impression of study medication, and in-
vestigator’s global impression of therapeutic response (PP population)
Study week Statistic APAP ER 1300 mg TID Rofecoxib 12.5 mg QD Rofecoxib 25 mg QD
Pain subscale*
Baseline n 123 125 117
Mean 288.64 288.08 311.82
1 n 119 122 114
Mean 185.33 180.55 175.52
Change from baseline 102.22 107.17 136.26
LSM change 103.18 109.77 128.65
Difference in LSMy e 6.59 25.48
95% CLz e 13.39, 26.56 5.01, 45.94
2 n 109 112 102
Mean 163.17 154.05 142.36
Change from baseline 122.82 132.72 166.14
LSM change 126.52 134.74 159.20
Difference in LSMy e 8.23 32.68
95% CLz e 14.84, 31.29 9.01, 56.36
4 n 103 109 100
Mean 150.35 136.25 127.98
Change from baseline 140.89 147.64 184.42
LSM change 143.46 154.43 175.93
Difference in LSMy e 10.97 32.46
95% CLz e 13.34, 35.27 7.54, 57.39
Physical function subscale*
Baseline n 121 125 116
Mean 970.55 990.34 1071.26
1 n 119 122 112
Mean 627.46 638.91 616.43
Change from baseline 338.42 355.54 457.97
LSM change 334.03 349.40 424.18
Difference in LSMy e 15.37 90.14
95% CLz e 54.17, 84.91 18.29, 162.00
2 n 109 112 102
Mean 573.18 561.53 526.65
Change from baseline 385.96 424.44 527.35
LSM change 420.99 442.90 534.44
Difference in LSMy e 21.91 113.45
95% CLz e 53.86, 97.68 35.39, 191.50
4 n 103 107 99
Mean 530.63 513.36 465.84
Change from baseline 448.32 470.95 598.74
LSM change 438.49 468.86 557.40
Difference in LSMy e 30.37 118.91
95% CLz e 51.37, 112.12 34.68, 203.14
Stiffness subscale*
Baseline n 123 125 117
Mean 117.28 123.06 131.30
1 n 119 122 114
Mean 75.45 82.59 73.77
Change from baseline 41.06 41.06 56.78
LSM change 41.61 38.85 50.86
Difference in LSMy e 2.76 9.25
95% CLz e 11.89, 6.37 0.12, 18.61
2 n 109 112 102
Mean 67.26 66.46 62.27
Change from baseline 50.94 55.80 66.99
LSM change 55.97 57.31 66.30
Difference in LSMy e 1.34 10.33
95% CLz e 8.44, 11.12 0.30, 20.37
4 n 103 108 100
Mean 65.63 60.36 55.01
Change from baseline 54.97 59.61 75.88
LSM change 55.48 60.19 70.72
Difference in LSMy e 4.71 15.23
95% CLz e 5.35, 14.77 4.89, 25.57
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Table II (continued )
Study week Statistic APAP ER 1300 mg TID Rofecoxib 12.5 mg QD Rofecoxib 25 mg QD
Study assessment
Patient’s overall impression of study medicationx
n 103 109 100
Mean 1.89 2.31 2.54
LSM change 1.87 2.29 2.53
Difference in LSMy e 0.43 0.67
95% CLz e 0.19, 0.67 0.42, 0.92
Investigator’s global impression of patient’s therapeutic responsex
n 103 108 100
Mean 1.99 2.31 2.63
LSM change 1.99 2.32 2.62
Difference in LSMy e 0.32 0.63
95% CLz e 0.08, 0.56 0.38, 0.87
*Using a VAS, maximum pain ranged from 0 to 500 mm, maximum physical function ranged from 0 to 1700 mm, and maximum stiffness
ranged from 0 to 200 mm.
yTreatment difference (rofecoxibAPAP ER) in LSM change.
zAPAP ER noninferiority¼ upper CL  50 mm for pain subscale, upper CL  170 mm for physical function subscale, and CL  20 mm for
stiffness subscale; CL reported as (lower, upper).
xScores range from 0 to 4; 0¼ poor, 1¼ fair, 2¼ good, 3¼ very good, 4¼ excellent.
5Osteoarthritis and Cartilage Vol. 17, No. 1treatment of pain associated with knee OA, because the up-
per one-sided 95% CL for the difference between APAP ER
and rofecoxib 12.5 mg in the LSM change from baseline
WOMAC pain subscale score at week 4 did not exceed
the predeﬁned limit of 50 mm (Table II, Fig. 2). For APAP
ER and rofecoxib 25 mg, the upper one-sided 95% CL for
the LSM change from baseline WOMAC pain subscale
score at week 4 exceeded 50 mm. These results did not
provide sufﬁcient evidence to establish the noninferiority
of APAP ER to rofecoxib 25 mg (Fig. 3). Primary efﬁcacy re-
sults from the ITT population were consistent with those ob-
tained from the PP population.
Results from the secondary end points correlated with
those from the primary end points. The upper one-sided
95% CL for the difference between APAP ER and rofecoxib
12.5 mg in the LSM change from baseline WOMAC physi-
cal function and stiffness subscale scores did not exceed
170 and 20 mm, respectively, establishing noninferiority of
APAP ER to rofecoxib 12.5 mg (Table II). Because the up-
per one-sided 95% CLs exceeded the limits in the rofecoxib
25-mg analysis, noninferiority of APAP ER to rofecoxib
25 mg could not be established for physical function and
stiffness. All other secondary end point results were consis-
tent with conclusions from the WOMAC pain, physical func-
tion, and stiffness tests (Table II). Results obtained from the
ITT population for the secondary efﬁcacy end points were
consistent with the PP population.SAFETY RESULTSAll study medications were well tolerated, with no signiﬁ-
cant differences in the overall nature or severity of AEs,
drug-related AEs, or discontinuations because of AEs
among treatment groups (Table III). Numerically, more
drug-related AEs were reported in the APAP ER group.
One patient in the APAP ER group and three patients in
the rofecoxib 12.5-mg group experienced serious AEs.
The patient in the APAP ER group had larynx edema, con-
sidered possibly related to study medication. Two of the se-
rious AEs in the rofecoxib 12.5-mg group were myocardial
infarctions, which were deemed unrelated to study medica-
tion. There were no myocardial infarctions or strokes re-
ported in the other treatment groups.Discussion
This study established the noninferiority of APAP ER
3900 mg daily to rofecoxib 12.5 mg daily in relieving pain
associated with knee OA, as measured by the WOMAC
pain subscale. Results from the secondary efﬁcacy end
points correlated well with those from the primary end point,
and established the noninferiority of APAP ER 3900 mg
daily to rofecoxib 12.5 mg daily in improving physical func-
tion and relieving stiffness. In the population studied, the
noninferiority of APAP ER to rofecoxib 25 mg daily could
not be established. The AEs reported were similar among
treatment groups, and both study drugs were well tolerated.
Several guidelines committees for the management of
OA recommend APAP as a ﬁrst-line therapy1,15. In a 2006
Cochrane review involving the pooled data of ﬁve random-
ized controlled trials that compared APAP with placebo,
APAP demonstrated a modest improvement in pain relief
compared with placebo19. Patient compliance with a dosing
regimen may be improved with an ER formulation because
fewer daily doses are required23. In addition, ER formula-
tions may maintain more constant drug levels in the
blood23,24. APAP ER 1300 mg administered three times
daily effectively managed pain in a 12-week, randomized,
placebo-controlled study involving patients with hip or
knee OA16. The availability of an ER formulation of APAP
may be more convenient for patients who require consistent
analgesia to manage OA pain.
Previous OA trials have suggested that patients experi-
ence superior pain relief with NSAIDs compared with
APAP19,25e28. A study conducted by Geba et al.18 showed
that the pain relief afforded by rofecoxib 12.5 mg and 25 mg
daily was greater than that observed with APAP in patients
with knee OA. Unlike the previous study, however, this
study established that APAP ER 3900 mg daily was nonin-
ferior to rofecoxib 12.5 mg daily in treating knee OA pain.
However, consistent with Geba’s study, noninferiority of
APAP to rofecoxib 25 mg daily could not be demonstrated.
In another trial, patients with mild to moderate OA pain ex-
perienced comparable pain relief with APAP 4000 mg daily
and ibuprofen 1200 mg daily29. A more recent study evalu-
ating APAP for hip or knee OA established that APAP
4000 mg daily was well tolerated and had efﬁcacy similar
Table III
Adverse Events*
Evaluation APAP ER
1300 mg TID
(n¼ 136)
Rofecoxib
12.5 mg QD
(n¼ 138)
Rofecoxib
25 mg QD
(n¼ 129)
Summary of all AEs
Patients with AEs 59 (43.4) 58 (42.0) 55 (42.6)
Patients with
serious AEs
1 (0.7) 3 (2.2) 0 (0.0)
Patients with
drug-related AEs
43 (31.6) 36 (26.1) 38 (29.5)
Patients who discontinued
because of AEs
8 (5.9) 9 (6.5) 9 (7.0)
Deaths 0 (0.0) 0 (0.0) 0 (0.0)
Drug-related AEs that occurred in at least 3% of any subgroup
Abdominal pain 5 (3.7) 2 (1.4) 0 (0.0)
Constipation 5 (3.7) 1 (0.7) 0 (0.0)
Diarrhea 10 (7.4) 4 (2.9) 4 (3.1)
Dizziness 2 (1.5) 2 (1.4) 5 (3.9)
Dyspepsia 7 (5.1) 4 (2.9) 3 (2.3)
Flatulence 4 (2.9) 2 (1.4) 4 (3.1)
Nausea 4 (2.9) 8 (5.8) 6 (4.7)
Headache 9 (6.6) 1 (0.7) 7 (5.4)
Pain 8 (5.9) 3 (2.2) 0 (0.0)
Peripheral edema 2 (1.5) 3 (2.2) 4 (3.1)
*All values shown as n (%).
200
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60
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Study Week
3 4
Rofecoxib 12.5 mg
Rofecoxib 25 mg
APAP ER
Fig. 2. Mean change from baseline WOMAC pain subscale in the
PP population at weeks 1, 2, and 4.
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on the ﬁndings in the present study and those of other stud-
ies, APAP may be an effective alternative to rofecoxib and
other NSAIDs for relief of mild to moderate pain.
In this relatively short trial, few AEs were reported. Al-
though there have been concerns regarding abnormal liver
function demonstrated even in short-term trials of APAP at
the maximum recommended dose of 4000 mg daily31, a ret-
rospective review of seven studies involving 1530 patients
taking APAP for up to 12 months at 1950e4000 mg daily
showed only low-level, transient alanine aminotransferase
elevations that either resolved or decreased with continued
APAP therapy32. In the retrospective review, no clear risks
of GI bleeding, cardiovascular events, or renal failure with
APAP were identiﬁed. Although overdosage with APAP
can result in hepatic toxicity, it is also the drug of choice
in individuals with renal and hepatic insufﬁciency who re-
quire an analgesic agent for mild to moderate pain. There
were no hepatic abnormalities noted in the present study.
Limitations of the present study include the lack of a pla-
cebo group, relatively short duration, lack of liver enzyme
testing, and the exclusion of patients with active inﬂamma-
tion of the study joint after the washout period. It should be
noted that the inclusion of a placebo group often makes50
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Fig. 3. LSM change from baseline in WOMAC pain subscale in the
PP population at week 4.accrual into such studies more difﬁcult, despite the availabil-
ity of escape therapy for escalating pain. Additionally, a pla-
cebo arm requires the enrollment of many more patients
into the study to account for the anticipated high number
of dropouts who fail on placebo therapy. In a 12-week study
evaluating APAP ER for knee OA pain, the superiority of
APAP ER compared with placebo was demonstrated as
early as 4 weeks16. Because the intent of the present study
was to determine efﬁcacy comparable to a COX-2-selective
inhibitor, a longer study was deemed unnecessary. Al-
though liver enzyme testing was not performed in this study,
it has been extensively studied, as described earlier31,32.
Another limitation of this study is that the effect of multi-
modal therapy (e.g., combined analgesic, anti-inﬂamma-
tory, topical, and intra-articular agents) was not assessed.
It is not known if combined therapy would be more effective
than separate therapies. Finally, the exclusion of patients
who had signs of active inﬂammation of the study joint limits
the generalizability of these results.
APAP ER 3900 mg daily was well tolerated and noninfe-
rior to rofecoxib 12.5 mg daily for the treatment of mild to
moderate pain associated with knee OA, but noninferiority
could not be established to rofecoxib 25 mg daily. Adverse
GI and cardiovascular events associated with traditional
NSAIDs and COX-2-selective inhibitors warrant a reevalua-
tion of their risks and beneﬁts and highlight the need for
a safer analgesic alternative. Based on the results of this
study, and consistent with published guidelines, APAP ER
should be considered as an alternative to NSAIDs for
the treatment of mild to moderate pain associated with
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